Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of HLH patients previously treated with NI-0501
NL-OMON48933Phase 2Withdrawn
- Sponsor
- Sobi
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of emapalumab in haemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS), sponsored by Sobi. Primary endpoints: Long-term safety profile, Overall survival after NI-0501 treatment and 7 more. Planned start Oct 2018; status: withdrawn.
02
Drugs
emapalumab
03
Conditions
haemophagocytic lymphohistiocytosis (HLH)macrophage activation syndrome (MAS)
Beyond the preview
Go deeper on NL-OMON48933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48933.